Terms: = Skin cancer AND ABL2, ARG, 27, ENSG00000143322, P42684, ABLL, RP11-177A2_3 AND Clinical Outcome
508 results:
1. clinical determinants of clinical response to Sonidegib in advanced basal cell carcinoma: a monocenter experience.
Spallone G; Carbone A; Sperati F; Frascione P; Eibenschutz L
Eur Rev Med Pharmacol Sci; 2024 Apr; 28(7):2923-2928. PubMed ID: 38639529
[TBL] [Abstract] [Full Text] [Related]
2. Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study.
Christensen SK; Winther ML; Laursen IJ; Madsen FS; Brink C; Brix TH; Ellebaek E; Svane IM; Hansen FS; Haslund C; Laursen OK; Schmidt H; Larsen ID; Bastholt L; Ruhlmann CH
Support Care Cancer; 2024 Apr; 32(5):281. PubMed ID: 38598052
[TBL] [Abstract] [Full Text] [Related]
3. B7-H3 is associated with the armored-cold phenotype and predicts poor immune checkpoint blockade response in melanoma.
Shen B; Mei J; Xu R; Cai Y; Wan M; Zhou J; Ding J; Zhu Y
Pathol Res Pract; 2024 Apr; 256():155267. PubMed ID: 38520953
[TBL] [Abstract] [Full Text] [Related]
4. Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma.
Roshardt Prieto NM; Turko P; Zellweger C; Nguyen-Kim TDL; Staeger R; Bellini E; Levesque MP; Dummer R; Ramelyte E
Melanoma Res; 2024 Apr; 34(2):166-174. PubMed ID: 38126339
[TBL] [Abstract] [Full Text] [Related]
5. Intratumoural and systemic inflammation as predictors for treatment response in BRAF-mutated melanoma patients under targeted therapies.
Gambichler T; Iordanou M; Becker JC; Susok L
Melanoma Res; 2024 Feb; 34(1):80-83. PubMed ID: 37924529
[TBL] [Abstract] [Full Text] [Related]
6. Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial.
Noviello TMR; Di Giacomo AM; Caruso FP; Covre A; Mortarini R; Scala G; Costa MC; Coral S; Fridman WH; Sautès-Fridman C; Brich S; Pruneri G; Simonetti E; Lofiego MF; Tufano R; Bedognetti D; Anichini A; Maio M; Ceccarelli M
Nat Commun; 2023 Sep; 14(1):5914. PubMed ID: 37739939
[TBL] [Abstract] [Full Text] [Related]
7. A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome.
Marsiglio J; McPherson JP; Kovacsovics-Bankowski M; Jeter J; Vaklavas C; Swami U; Grossmann D; Erickson-Wayman A; Soares HP; Kerrigan K; Gibson B; Doherty JA; Hyngstrom J; Hardikar S; Hu-Lieskovan S
Front Immunol; 2023; 14():1229823. PubMed ID: 37671166
[TBL] [Abstract] [Full Text] [Related]
8. Molecular Features of Resected Melanoma Brain Metastases, clinical outcomes, and Responses to Immunotherapy.
Vasudevan HN; Delley C; Chen WC; Mirchia K; Pan S; Shukla P; Aabedi AA; Nguyen MP; Morshed RA; Young JS; Boreta L; Fogh SE; Nakamura JL; Theodosopoulos PV; Phillips J; Hervey-Jumper SL; Daras M; Pike L; Aghi MK; Tsai K; Raleigh DR; Braunstein SE; Abate AR
JAMA Netw Open; 2023 Aug; 6(8):e2329186. PubMed ID: 37589977
[TBL] [Abstract] [Full Text] [Related]
9. Effect of lidocaine spray on reliving non-coring needle puncture-related pain in patients with totally implantable venous access port: a randomized controlled trial.
Zhu Y; Niu S; Zhang Y; Zhang H; Chang J; Ye L
Support Care Cancer; 2023 Jul; 31(8):452. PubMed ID: 37421451
[TBL] [Abstract] [Full Text] [Related]
10. BRAFV600 variant allele frequency predicts outcome in metastatic melanoma patients treated with BRAF and MEK inhibitors.
Mandalà M; Palmieri G; Ludovini V; Baglivo S; Marasciulo F; Castiglione F; Gili A; Osella Abate S; Rubatto M; Senetta R; Avallone G; Ribero S; Romano L; Pimpinelli N; de Giorgi V; Roila F; Pisano M; Casula M; Manca A; Sini MC; Massi D; Quaglino P;
J Eur Acad Dermatol Venereol; 2023 Oct; 37(10):1991-1998. PubMed ID: 37335879
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic Factors of Pretreatment Magnetic Resonance Imaging for Predicting clinical outcome in Patients With Parotid Gland cancer.
Ando T; Kato H; Shibata H; Ogawa T; Noda Y; Hyodo F; Matsuo M
J Comput Assist Tomogr; 2023 May-Jun 01; 47(3):507-513. PubMed ID: 37185018
[TBL] [Abstract] [Full Text] [Related]
12. A bibliometric and visualized research on global trends of immune checkpoint inhibitors related complications in melanoma, 2011-2021.
Zhang H; Shi Y; Ying J; Chen Y; Guo R; Zhao X; Jia L; Xiong J; Jiang F
Front Endocrinol (Lausanne); 2023; 14():1164692. PubMed ID: 37152956
[TBL] [Abstract] [Full Text] [Related]
13. Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE): a randomised, controlled, three-arm, parallel group, phase 3, clinical trial.
Kent P; Haines T; O'Sullivan P; Smith A; Campbell A; Schutze R; Attwell S; Caneiro JP; Laird R; O'Sullivan K; McGregor A; Hartvigsen J; Lee DA; Vickery A; Hancock M;
Lancet; 2023 Jun; 401(10391):1866-1877. PubMed ID: 37146623
[TBL] [Abstract] [Full Text] [Related]
14. A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study.
Gravis G; Marino P; Olive D; Penault-LLorca F; Delord JP; Simon C; Lamrani-Ghaouti A; Sabatier R; Ciccolini J; Boher JM
BMC Cancer; 2023 May; 23(1):393. PubMed ID: 37131154
[TBL] [Abstract] [Full Text] [Related]
15. Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions.
De Falco V; Suarato G; Napolitano R; Argenziano G; Famiglietti V; Amato A; Servetto A; Bianco R; Formisano L; Terrano V; Esposito A; Giugliano MC; Ciardiello D; Ciardiello F; Napolitano S; Troiani T
Int J Cancer; 2023 Jul; 153(1):133-140. PubMed ID: 36752579
[TBL] [Abstract] [Full Text] [Related]
16. Combined PD-1, BRAF and MEK inhibition in BRAF
Tian J; Chen JH; Chao SX; Pelka K; Giannakis M; Hess J; Burke K; Jorgji V; Sindurakar P; Braverman J; Mehta A; Oka T; Huang M; Lieb D; Spurrell M; Allen JN; Abrams TA; Clark JW; Enzinger AC; Enzinger PC; Klempner SJ; McCleary NJ; Meyerhardt JA; Ryan DP; Yurgelun MB; Kanter K; Van Seventer EE; Baiev I; Chi G; Jarnagin J; Bradford WB; Wong E; Michel AG; Fetter IJ; Siravegna G; Gemma AJ; Sharpe A; Demehri S; Leary R; Campbell CD; Yilmaz O; Getz GA; Parikh AR; Hacohen N; Corcoran RB
Nat Med; 2023 Feb; 29(2):458-466. PubMed ID: 36702949
[TBL] [Abstract] [Full Text] [Related]
17. outcomes of feeding jejunostomy after pancreaticoduodenectomy: A single-center experience.
Yamamoto N; Aoyama T; Murakawa M; Kamiya M; Shiozawa M; Rino Y; Masuda M; Morinaga S
J Cancer Res Ther; 2022 Dec; 18(Supplement):S444-S448. PubMed ID: 36511001
[TBL] [Abstract] [Full Text] [Related]
18. Discovery of pathway-independent protein signatures associated with clinical outcome in human cancer cohorts.
Konaté MM; Li MC; McShane LM; Zhao Y
Sci Rep; 2022 Nov; 12(1):19283. PubMed ID: 36369472
[TBL] [Abstract] [Full Text] [Related]
19. The Feasibility of Immunocryosurgery in the Treatment of Non-Superficial, Facial Basal Cell Carcinoma That Relapsed after Standard Surgical Excision: An Experience Report from Two Centers.
Gaitanis G; Zampeta A; Tsintzou P; Fillis G; Seretis K; Feldmeyer L; Bassukas I
Curr Oncol; 2022 Nov; 29(11):8475-8482. PubMed ID: 36354728
[TBL] [Abstract] [Full Text] [Related]
20. clinical management of melanocytic tumours of uncertain malignant potential (MelTUMPs), including melanocytomas: A systematic review and meta-analysis.
Varey AHR; Williams GJ; Lo SN; Taing CY; Maurichi A; Santinami M; Scolyer RA; Thompson JF
J Eur Acad Dermatol Venereol; 2023 May; 37(5):859-870. PubMed ID: 36251355
[TBL] [Abstract] [Full Text] [Related]
[Next]